A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

This is a phase I, open-label, first-in-human study of CS08399, comprising two phases: dose escalation (including single-dose and multiple-dose) and cohort expansion. The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of CS08399 in participants with MTAP-deleted solid tumors and Lymphoma, and to recommended Phase 2 dose(s) (RP2D) of CS08399 in appropriate tumor(s).

NCT Number	NCT07583771
Lead Sponsor	Chipscreen Biosciences, Ltd.
Conditions	Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment	186 participants
Start Date	2026-06
Primary Completion	2029-08 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-13